Breast cancer is not simply one disease, and the use of more effective therapies that target different tumor markers, such as the cyclin-dependent kinase (CDK)4/6 pathway in estrogen receptor–positive breast cancer, may actually reduce the total cost of care for patients/members and payers.
The Affordable Care Act (ACA), officially called the Patient Protection and Affordable Care Act, which began implementation in March 2010 and will not be fully implemented until 2018, has impacted oncology care in both positive and negative ways. Read More ›
